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Abstract: BACKGROUND We recently demonstrated that the measurement of Mycoplasma pneumoniae
(Mp)-specific immunoglobulin (Ig)M antibody-secreting cells (ASCs) improved diagnosis of Mp infection.
Here, we aimed to describe Mp ASC kinetics and duration in comparison to conventional measures such
as pharyngeal Mp deoxyribonucleic acid (DNA) and serum antibodies. METHODS This is a prospective
longitudinal study of 63 community-acquired pneumonia (CAP) patients and 21 healthy controls (HCs),
3-18 years of age, from 2016 to 2017. Mycoplasma pneumoniae ASCs measured by enzyme-linked im-
munospot assay were assessed alongside Mp DNA and antibodies during 6-month follow-up. RESULTS
Mycoplasma pneumoniae ASCs of the isotype IgM were found in 29 (46%), IgG were found in 27 (43%),
and IgA were found in 27 (43%) CAP patients. Mycoplasma pneumoniae ASCs were detected from 2
days to a maximum of 6 weeks after symptom onset, whereas Mp DNA and antibodies persisted until 4
months (P = .03) and 6 months (P < .01). Mycoplasma pneumoniae ASCs were undetectable in HCs,
in contrast to detection of Mp DNA in 10 (48%) or antibodies in 6 (29%) controls for a prolonged time.
The Mp ASC response correlated with clinical disease, but it did not differ between patients treated with
or without antibiotics against Mp. CONCLUSIONS Mycoplasma pneumoniae-specific ASCs are short-
lived and associated with clinical disease, making it an optimal resource for determining Mp pneumonia
etiology.
DOI: https://doi.org/10.1093/infdis/jiaa062





Meyer Sauteur, Patrick M; Trück, Johannes; van Rossum, Annemarie M C; Berger, Christoph (2020).
Circulating Antibody-Secreting Cell Response During Mycoplasma pneumoniae Childhood Pneumonia.
Journal of Infectious Diseases, 222(1):136-147.
DOI: https://doi.org/10.1093/infdis/jiaa062
Circulating antibody-secreting cell response during 1	
Mycoplasma pneumoniae childhood pneumonia 2	
 3	
Patrick M. Meyer Sauteur, MD PhD1,*, Johannes Trück, MD DPhil1,2, Annemarie M.C. van 4	
Rossum, MD PhD3, Christoph Berger, MD1 5	
 6	
1
 Division of Infectious Diseases and Hospital Epidemiology, University Children’s 7	
Hospital Zurich, Zurich, Switzerland 8	
2
 Division of Immunology, University Children’s Hospital Zurich, Zurich, Switzerland 9	
3
 Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, 10	




Patrick M. Meyer Sauteur, MD PhD 15	
Division of Infectious Diseases and Hospital Epidemiology 16	
University Children’s Hospital Zurich 17	
Steinwiesstrasse 75, CH-8032 Zurich, Switzerland 18	
Tel.: +41 44 266 78 96; Fax: +41 44 266 80 72 19	
E-mail: patrick.meyer@kispi.uzh.ch 20	
Alternate corresponding author: Christoph Berger, MD; christoph.berger@kispi.uzh.ch 21	
 22	
Conflict of interest: none. 23	
Running head: ASC response in Mp CAP. 24	
Word count: abstract: 200 (limit: 200), text: 3500 (limit: 3500). 25	
ASC response in Mp CAP	
Manuscript Page 2 
40-word-or-less summary of article’s main point 26	
Mycoplasma pneumoniae (Mp)-specific antibody-secreting cells (ASCs) are detectable in 27	
peripheral blood of children with Mp community-acquired pneumonia within the first 1–2 28	
weeks upon disease onset, and its presence is short-lived and associated with clinical disease. 29	
 30	
Abstract 31	
Background: We recently demonstrated that the measurement of Mycoplasma pneumoniae 32	
(Mp)-specific IgM antibody-secreting cells (ASCs) improved diagnosis of Mp infection. Here, 33	
we aimed to describe Mp ASC kinetics and duration in comparison to conventional measures 34	
such as pharyngeal Mp DNA and serum antibodies. 35	
Methods: Prospective longitudinal study of 63 community-acquired pneumonia (CAP) 36	
patients and 21 healthy controls (HCs), 3–18 years of age, from 2016–2017. Mp ASCs 37	
measured by enzyme-linked immunospot (ELISpot) were assessed alongside Mp DNA and 38	
antibodies during 6-month follow-up. 39	
Results: Mp ASCs of the isotype IgM were found in 29 (46%), IgG in 27 (43%), and IgA in 40	
27 (43%) CAP patients. Mp ASCs were detected from 2 days to maximum 6 weeks after 41	
symptom onset, while Mp DNA and antibodies persisted until 4 months (p=0.03) and 6 42	
months (p<0.01). Mp ASCs were undetectable in HCs, in contrast to detection of Mp DNA in 43	
10 (48%) or antibodies in 6 (29%) controls for prolonged time. The Mp ASC response 44	
correlated with clinical disease, but did not differ between patients treated with or without 45	
antibiotics against Mp. 46	
Conclusions: Mp-specific ASCs are short-lived and associated with clinical disease, making 47	
it an optimal resource for determining Mp pneumonia etiology. 48	
 49	
 50	
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Introduction 54	
Mycoplasma pneumoniae (Mp) is a common bacterial pathogen of community-acquired 55	
pneumonia (CAP) in children [1]. The “gold standard” for diagnosing Mp infection is a ≥4-56	
fold increase in antibody levels [2] but has low sensitivity [3] and is not helpful in acute 57	
clinical management as it requires acute and convalescent sera [4]. Single immunoglobulin 58	
(Ig) M levels against Mp, and Mp-specific polymerase chain reaction (PCR) on upper 59	
respiratory tract (URT) samples are currently used to diagnose Mp CAP [5, 6]. However, 60	
these diagnostic tests are also positive in asymptomatic carriers, and therefore are unable to 61	
differentiate between Mp infection and carriage [7]. We recently demonstrated that the 62	
measurement of Mp-specific IgM antibody-secreting cells (ASCs) by enzyme-linked 63	
immunospot (ELISpot) assay improved diagnosis of Mp infection: Mp-specific IgM ASCs 64	
were detectable in children with Mp CAP, but not in Mp carriers suffering from CAP caused 65	
by other pathogens or asymptomatic Mp carriers [8]. 66	
 67	
Previous work in vaccine studies has established that circulating antigen-specific B cell 68	
responses are more rapid and shorter lived than antibody responses [9, 10]. Antigen-specific 69	
B cells proliferate and differentiate after antigen exposure into ASCs and memory B cells [11, 70	
12]. ASCs then circulate in the peripheral blood for up to two weeks before migrating to 71	
secondary lymphoid organs or bone marrow, or undergoing apoptosis [12, 13]. However, data 72	
on the human B-cell response during infection rather than following controlled antigen 73	
challenge via vaccination are scarce. In a longitudinal follow-up of our recent study [8], we 74	
aimed to describe the onset, kinetics, duration, and isotype of the antigen-specific plasmablast 75	
response following Mp infection in children in comparison to more conventional measures 76	
such as Mp DNA in the URT and serum antibody responses. We further evaluated the effect 77	
of different treatment regimens against Mp on the ASC response and these other measures. 78	
 79	
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Methods 80	
Ethics statement 81	
The ethics committee of Zurich, Switzerland, approved the protocol for this study (no. 2016-82	
00148). Written informed consent was obtained from all parents and from children from 14 83	
years of age. 84	
 85	
Participants 86	
We consecutively enrolled patients between May 1, 2016, and April 30, 2017, at University 87	
Children’s Hospital Zurich. In all children pharyngeal swab specimens were taken. Blood 88	
samples were collected if additional consent was given. All participants were invited to 89	
participate in this longitudinal follow-up study with additional visits between enrollment–2 90	
weeks, 2 weeks–2 months, and/or 2–6 months after presentation. 91	
 92	
CAP patients 93	
CAP was defined as a clinical diagnosis of pneumonia in previously healthy children aged 3–94	
18 years, as detailed elsewhere [8, 14]. Trained physicians identified cases at the emergency 95	
department and on pediatric wards. CAP patients <3 years of age were excluded to reduce the 96	
probability of viral infection, as it is highest in this age group [1, 15-17]. CAP patients were 97	
managed by treating physicians, who were not aware of the study test results, and treated 98	
according to current guidelines [5, 6]. 99	
 100	
Healthy controls (HCs) 101	
HCs included healthy children undergoing elective surgical procedures and siblings of CAP 102	
patients. Healthy children undergoing elective surgical procedures were age-matched and 103	
excluded if there was a history of a recent (≤1 week) respiratory tract infection. Samples were 104	
collected at enrollment by the attending anesthesiologist before surgery while the child was 105	
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under general anesthesia. We also recruited and followed siblings of CAP patients without 106	
evidence of recent respiratory tract infection. 107	
 108	
Study procedures 109	
Collection of biological samples 110	
Swabs were taken from the posterior pharynx using flocked nylon fiber tip swabs (Copan 111	
Diagnostics, Murrieta, CA, USA). Blood samples were collected in anticoagulated lithium 112	
heparin blood collection tubes and fresh peripheral blood mononuclear cells (PBMCs) were 113	
isolated ≤4 h after sampling to avoid poor assay performance due to decreased ASC viability. 114	
PBMCs were isolated by density gradient centrifugation with Ficoll-Paque PLUS (GE 115	
Healthcare, Uppsala, Sweden) and viability assessed by trypan blue exclusion. Serum was 116	
stored at –80°C. 117	
 118	
Mp real-time PCR 119	
DNA isolation was performed on pharyngeal swab samples with the QIAamp DNA Mini Kit 120	
(Qiagen, Hilden, Germany). A quantitative TaqMan (Applied Biosystems, Foster City, CA, 121	
USA) real-time PCR assay was used to detect and quantify Mp DNA as described previously 122	
[18]. 123	
 124	
Mp-specific enzyme-linked immunosorbent assay (ELISA) 125	
Mp-specific IgM, IgG, and IgA antibody levels were determined using a commercially 126	
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Mp-specific ASC ELISpot assay 132	
The frequency of circulating Mp-specific IgM ASCs was measured by ELISpot assays using 133	
fresh PBMCs, as described previously [19], with some modifications. Briefly, 96-well 134	
ELISpot filter plates (Millipore, Billerica, MA, USA) were coated for 90 min at 37°C with the 135	
different antigens diluted in sterile phosphate-buffered saline (PBS). The antigens were: 136	
detergent extract of Mp enriched for highly specific adhesion protein P1 (2 µg/ml; 137	
Virion\Serion, Würzburg, Germany); Fluarix® Tetra quadrivalent influenza A and B virus 138	
vaccine (6 µg/ml; GlaxoSmithKline, Middlesex, UK); and affinity-purified antibodies to 139	
human Ig light chains (λ and κ, 10 µg/ml; Southern Biotech, Birmingham, AL, USA) as the 140	
positive control. The negative control consisted of PBS only in uncoated wells. After 141	
washing, coated plates were blocked with medium for another 90 min at 37°C. Coated plates 142	
were incubated at 37°C for 16–20 h with 100,000 or 10,000 viable PBMCs, and each dilution 143	
was used in triplicate. Plates were then washed, incubated with biotinylated anti-IgM, -IgG, -144	
IgA and alkaline phosphatase (AP)-conjugated streptavidin (all Southern Biotech), and spots 145	
visualized using an AP substrate kit (Bio-Rad Laboratories, Hercules, CA, USA), with each 146	
spot appearing at the former location of a single ASC. Spots were counted by an ELISpot 147	
reader (AID, Strassberg, Germany) using pre-defined settings. The spots identified by the 148	
machine were manually inspected for the presence of artifacts. Antigen-specific spot counts 149	
were calculated as the mean of three wells minus the mean number of spots in PBS wells. 150	
Data were expressed as ASCs per 106 viable PBMCs [19]. 151	
 152	
Statistical analysis 153	
We report dichotomous variables as percentages and continuous variables as medians with 154	
interquartile ranges (IQRs). The Mann-Whitney U test was used to compare medians, and the 155	
Fisher’s exact test to compare proportions. Spearman rank correlation was used to evaluate 156	
relationships between variables. Kinetics were plotted with smooth curves, fitted by loess 157	
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(with a span of 0.67) using the scatter.smooth formula [20]. Study design and sample size 158	
considerations were described in detail previously [8]. All reported p-values are 2-tailed with 159	
statistical significance defined as p-value <0.05. Data were analyzed using the R software 160	




During the 12-month study period, we screened 450 CAP patients and 156 HCs (Figure 1). A 165	
total of 152 CAP patients and 156 HCs were enrolled (Table 1). Mp-specific PCR and 166	
serological test results of the enrolled population are shown in Table 2. Thereof, we included 167	
63 CAP patients and 21 HCs with fresh (isolated ≤4 h) PBMCs available for additional testing 168	
with the Mp-specific ASC ELISpot assay, as previously reported [8]. There were no 169	
statistically significant differences between included and overall enrolled CAP patients and 170	
HCs in regards to age, sex, and season at enrollment (Table 1). However, the proportion of 171	
siblings of index patients among HCs was higher in the included group of controls compared 172	
to enrolled controls (43% vs. 12%, p<0.01). Clinical, radiological, and laboratory 173	
characteristics of included CAP patients have been described separately [14, 21]. 174	
 175	
Kinetics and duration of the ASC response 176	
We first assessed the ASC response at presentation and found Mp-specific ASCs in CAP 177	
patients (n=63) of the isotype IgM, IgG, and IgA in 29 (46%), 27 (43%), and 27 (43%), 178	
respectively (Table 2). These first samples were collected at a median of 12 days after onset 179	
of symptoms (IQR 11–16, range 2–29). Then, the median number of Mp IgM ASCs was 690 180	
(IQR 200–1,933) spots per 106 PBMCs, which was higher than that of Mp IgG ASCs (median 181	
300, IQR 166–533; p=0.07) and Mp IgA ASCs (median 167, IQR 67–333; p<0.01). Mp IgM 182	
ASCs correlated with Mp IgG ASCs (rho 0.63, p<0.01) and Mp IgA ASCs (rho 0.62, p<0.01), 183	
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but not with Mp antibody (any isotype) or Mp DNA levels (Supplementary Table 1). Time 184	
since onset of symptoms positively correlated with Mp IgM and Mp IgG antibody levels (rho 185	
0.56 and 0.53, p<0.01), but not with Mp ASCs (any isotype), in first measured sample 186	
(Supplementary Table 2). Among HCs (n=21), no Mp ASCs were detected, but Mp IgM 187	
serology was positive in 6 (29%) individuals, of whom 1 (5%) showed seroconversion to Mp 188	
IgG with a >4-fold increase in Mp IgG (Table 2). All 29 Mp IgM ASC-positive CAP patients 189	
were also Mp PCR-positive and Mp IgM-positive, and the 3 (5%) Mp PCR-positive patients, 190	
who were Mp IgM ASC- and Mp IgM-negative, were identified as Mp carriers suffering from 191	
CAP caused by other pathogens, as detailed elsewhere [8]. The specificity of the Mp IgM 192	
ASC ELISpot assay was further demonstrated by the absence of Mp IgM ASCs in influenza 193	
virus [14] and Epstein-Barr virus (EBV) [22] infected patients (Supplementary Figure 1). 194	
The 2 patients who tested positive for influenza virus in pharyngeal swab samples [14] had 195	
influenza-specific but not Mp-specific ASCs detectable during CAP. 196	
 197	
The longitudinal follow-up study included 52 (62%) children (41 CAP patients and 11 HCs) 198	
with >2 visits in 42 (81%) and >3 visits in 27 (52%) children, performed at <2 weeks, 2 199	
weeks–2 months, and 2–6 months in 43 (83%), 38 (73%), and 38 (73%) individuals, 200	
respectively. Mp ASCs were detected only within 6 weeks after symptom onset (Figure 2), in 201	
contrast to Mp DNA (p=0.03) and Mp IgM and Mp IgG (p<0.01) persisting at 4 and 6 months, 202	
respectively (Supplementary Table 3). The Mp IgA levels in CAP patients were low 203	
(median 11 U/ml, IQR 6–25) and above the cut-off in only 13 (21%) (Table 2), and differed 204	
significantly from Mp IgM (p<0.01) and Mp IgG (p<0.01) levels. However, Mp antibody 205	
levels and kinetics correlated between isotypes (Supplementary Table 1 and Figure 2). 206	
Detecting a ≥4-fold Mp IgG increase in Mp IgM ASC-positive patients was significantly more 207	
likely with Mp IgG <20 U/ml (91%, n=10/11) compared to Mp IgG ≥20 U/ml (0%, n=0/18; 208	
p<0.01) at presentation. 209	
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 210	
Interestingly, 3 siblings of CAP patients developed CAP during follow-up and were then also 211	
tested positive for Mp IgM ASCs. One of the 3 siblings was sampled (as asymptomatic 212	
sibling of a CAP patient) 3 days prior to the onset of symptoms, and at this time point, tested 213	
negative by the Mp ASC ELISpot assay, followed by a positive Mp ASC ELISpot assay result 214	
6 days after developing symptoms and CAP diagnosis. Representative Mp IgM ASC ELISpot 215	
assay responses in this patient are shown in Figure 3. The kinetics of Mp DNA, Mp 216	
antibodies, and Mp ASCs of this patient are indicated in black in Supplementary Figure 2. 217	
 218	
In HCs, Mp DNA and/or Mp IgM and IgG were detected for up to ≥2 months, while Mp 219	
ASCs and Mp IgA levels were negative during the complete 6-month follow-up period 220	
(Figure 4). These results were in line with the lack of respiratory symptoms during follow-up 221	
visits. 222	
 223	
Relation of the ASC response with clinical disease 224	
We next compared the ASC response with clinical disease. As previously demonstrated in 225	
this cohort [14], Mp IgM ASC-positive CAP was statistically associated with prolonged 226	
prodromal symptoms and extrapulmonary manifestations, predominantly skin disorders [21]. 227	
However, the magnitude of the Mp-specific ASC response did not correlate with any of these 228	
clinical features (Supplementary Table 2). Further, lower levels of C-reactive protein (CRP), 229	
white blood cell (WBC) count, absolute neutrophil count (ANC), and procalcitonin were 230	
statistically associated with IgM ASC-positive Mp infection [14]. Mp IgM ASC responses 231	
correlated positively with CRP levels (rho 0.45; p=0.01), and negatively with WBC count 232	
(rho -0.61; p<0.01) and ANC (rho -0.66; p<0.01), but not with other laboratory parameters 233	
(Supplementary Table 2). 234	
 235	
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Next, we evaluated the effect of different treatment regimens against Mp on the ASC 236	
response. Ten (34.5%) patients received clarithromycin, 10 (34.5%) patients received 237	
doxycycline, and 9 (31%) patients were not treated with any antibiotic in vitro active against 238	
Mp (i.e., amoxicillin, n=5, amoxicillin-clavulanate, n=1, ceftriaxone, n=1, no antibiotic 239	
treatment, n=2). Kinetics of pharyngeal Mp DNA, Mp-specific antibodies, and Mp ASCs 240	
according to different treatment management are shown in Figure 5. There were no 241	
statistically significant differences between patients with or without treatment in vitro active 242	
against Mp with regards to ASC and antibody responses (Supplementary Table 4). In 243	
contrast, Mp DNA was detected in patients treated with clarithromycin and doxycycline in 244	
58% and 90% at 1–2-month follow-up (p=0.01) and 38% and 0% at 3–4-month follow-up 245	
(p=0.20), respectively. Notably, clinical outcome (length of hospital stay and long-term 246	
sequelae) and fever duration was not statistically different between treatment groups 247	
(Supplementary Figure 3). Five patients who received antibiotics against Mp were 248	
additionally treated with corticosteroids because of severe extrapulmonary mucocutaneous 249	
manifestations [21]. Mp IgM ASC numbers did not differ between those patients before 250	
corticosteroid treatment and other CAP patients at an early time point (<2 weeks after onset of 251	
symptoms) (p=0.49), but were significantly lower at a later time point (2–4 weeks after onset 252	
of symptoms) following the administration of corticosteroids compared to CAP patients 253	




In this longitudinal follow-up study, we demonstrate that Mp-specific ASCs are short-lived 258	
and associated with clinical disease, in contrast to pharyngeal Mp DNA and serum antibodies 259	
that can persist for months and may be present also during Mp carriage. This study adds to 260	
our recent work [8] by detailing the onset, kinetics, duration, and isotype (IgM/IgG/IgA) of 261	
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the antigen-specific plasmablast response following Mp infection in children and 262	
investigating the effect of different treatment regimens against Mp on the specific immune 263	
response and pharyngeal Mp DNA load. These findings expand our current knowledge on 264	
specific B-cell responses to infection and provide an explanation for the high specificity and 265	
sensitivity of the Mp ASC ELISpot assay during Mp CAP [8]. The data presented give insight 266	
into disease pathophysiology and can therefore serve as a model for developing better 267	
diagnostic tests for other childhood infectious diseases. 268	
 269	
We detected Mp ASCs as early as 2 days after the presentation of clinical symptoms, which 270	
was in line with the only previous study on Mp-specific ASCs including 12 Mp-seropositive 271	
children with CAP, in which Mp ASCs were detected within 5 days after symptom onset [23]. 272	
To our knowledge, we assessed also for the first time B-cell responses in a patient shortly 273	
prior to the development of symptoms and could thereby exemplarily demonstrate a specific 274	
ASC response upon CAP onset, which disappeared again with disease resolution, while Mp 275	
DNA and antibodies persisted for prolonged time. Mp-specific ASCs peaked around 1–2 276	
weeks, similar to previous work: We recently reviewed the literature on the ASC response to 277	
infection [9] and found that the timing of ASC appearance in the blood is highly consistent 278	
after infection across several pathogens. ASCs are first detectable in peripheral blood at 279	
around 4 days following onset of symptoms before peaking at days 6–8 [9, 24]. In contrast to 280	
the conserved timing of ASC appearance, the magnitude of ASC responses varies widely 281	
between different bacterial and viral pathogens as well as between ASC isotypes [9]. Our 282	
results are consistent with previous work studying the immune responses to both vaccination 283	
[13] and infection [9], and demonstrate a synchronized response of B cells with different 284	
isotypes during infection. Conversely, serum antibody responses showed a sequential 285	
appearance in our study: IgM and IgA were first detectable followed by IgG with 286	
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concentrations that were still rising in the first 4 weeks following symptom onset, and lasting 287	
for several months. 288	
 289	
However, in some individuals, B-cell responses could be detected up to 6 weeks following 290	
onset of symptoms indicating that Mp-specific ASCs may circulate longer compared with 291	
other (respiratory) infections, in which antigen-specific ASCs disappeared in most cases 292	
already 14 days after symptoms onset [9, 25-30]. These findings support the clinical 293	
observation of slow disease progression in Mp CAP [14], which may result in a longer 294	
antigen exposure and therefore immune activation allowing to detect Mp-specific ASCs in all 295	
patients during CAP. A more prolonged antigen exposure with slow disease progression may 296	
also be the reason for the significantly increased Mp IgG levels already in the first serum 297	
sample of Mp IgM ASC-positive CAP patients. The development of a further increase of Mp 298	
IgG in those patients ≥4-fold was therefore very unlikely which continues to question its 299	
value as “gold standard” for diagnosing Mp infection [3, 4]. Its interpretation is also 300	
complicated by our observation of a >4-fold increase in Mp IgG level in an asymptomatic 301	
sibling. 302	
 303	
Besides describing Mp ASC response kinetics and duration, we also determined antibody 304	
specificity and isotype of the plasmablast response to infection, which are key to develop 305	
accurate ASC measurements [9]. We showed that Mp-specific ASCs were not detectable in 306	
patients infected with influenza virus or EBV, while patients with influenza virus infection on 307	
the other hand developed influenza virus-specific ASCs during CAP. The detection of Mp 308	
IgM ASCs was more sensitive than the detection of Mp IgG ASCs or Mp IgA ASCs for 309	
determining Mp infection, again in line with previous work [23]. 310	
 311	
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The Mp-specific ASC response was associated with clinical disease and correlated with CRP 312	
levels and WBC counts. Although Mp CAP was associated with lower CRP levels compared 313	
to CAP of other origin [14], severe disease defined as the presence of extrapulmonary skin 314	
manifestations was associated with increased systemic inflammation and higher CRP levels 315	
[21]. This finding suggests that in these children, inflammation may be indeed driven by Mp 316	
antigens, which warrants further investigation. Interestingly, there were no differences in ASC 317	
or antibody responses, or clinical outcomes such as fever duration, between groups with 318	
different antibiotic treatment regimens. In contrast, corticosteroid treatment significantly 319	
decreased ASC responses, although they were still detectable. One-third of Mp IgM ASC-320	
positive CAP patients were not treated with an antibiotic in vitro active against Mp, but all of 321	
them equally and fully recovered. Although the study design does not allow conclusions 322	
about the effectiveness of treatment these findings highlight the need for future interventional 323	
studies to assess the efficacy of antibiotics for Mp CAP [2, 31]. 324	
 325	
The ASC ELISpot assay is a robust technique [9, 32], and the protocol described here could 326	
be translated directly into the clinical setting to diagnose Mp infection by using only a small 327	
volume of peripheral blood (≥1 ml). Yet, the ASC ELISpot assay is labor-intensive requiring 328	
the handling of fresh or frozen PBMCs [19, 32] and has a rather long overall turnaround time 329	
(~24 h), but recent alternative protocols suggest more rapid (~6–8 h) ASC detection [19]. 330	
Optimizing such protocols will help to routinely use the Mp IgM ASC ELISpot assay for 331	
diagnosing Mp CAP. 332	
 333	
Despite variation in sampling time points, the study population represents a well-defined 334	
cohort of children, both patients and controls, in whom pharyngeal swabs and fresh blood 335	
samples at several time points up to 6 months following inclusion could be obtained. It is 336	
challenging to collect blood samples from healthy children and already recovered children 337	
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and we can therefore not fully exclude any selection bias that occurred in the included 338	
subgroup of study participants. However, baseline characteristics of both included CAP 339	
patients and controls were similar compared with the enrolled study population. Some of the 340	
siblings of index patients were included as controls, which made it possible to increase the 341	
likelihood of detecting asymptomatic Mp carriers and to investigate the pattern symptom 342	
acquisition and/or changes in the results of the diagnostic tests. Mp was indeed more 343	
frequently detected in the URT of siblings compared to HCs sampled during elective surgery 344	
(32% vs. 4%), which is in line with a higher Mp transmission rate within families and 345	
between other close contacts [14, 33, 34]. Proportionally, more siblings than other controls 346	
were included than were initially enrolled into the study (43% vs. 12%), which may be partly 347	
due to a higher motivation of family members of affected patients agreeing to multiple 348	
sampling and follow-up. This may also explain the differences in Mp detection rates between 349	
included and enrolled study participants. A larger prospective confirmatory study is needed to 350	
validate these promising results of the Mp ASC ELISpot assay and to examine the added 351	
clinical utility of the ASC ELISpot assay to diagnose Mp infection in the clinical care of 352	
children with CAP. 353	
 354	
In conclusion, Mp-specific ASCs are short-lived and associated with clinical disease, in 355	
contrast to pharyngeal Mp DNA and serum antibodies. There are limited data on the duration 356	
of B-cell responses during infection and our study indicates that Mp-specific peripheral blood 357	
B cells appear early in the course of illness, last only for several weeks before disappearing 358	
completely so that they can be easily detected in a clinical setting with good diagnostic 359	
sensitivity and specificity. These findings expand our current knowledge on specific B-cell 360	
responses to infection, and reveal ASCs as an optimal resource for determining disease 361	
etiology in Mp pneumonia and possibly other childhood infections. 362	
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Tables 488	
Table 1. Baseline characteristics of CAP patients and controls. 489	
Characteristics CAP  
 










n=12 (57) elective 
surgery 





n=137 (88) elective 
surgery 
n=19 (12) siblings 
 
Age (years), median (IQR) 
 
 
6.0 (4.4–10.2) 5.7 (4.3–8.9) 6.1 (4.9–7.9) 
 
5.9 (4.3–8.1) – 0.91 
Sex (male), n (%) 
 
 
39 (62) 84 (55) 17 (81) 102 (65) 0.4 (0.1–1.4) 0.18 
Season at enrollment, n (%): 
 
      
- Spring (March–May) 11 (17) 21 (14) 5 (24) 43 (28) 0.7 (0.2–2.9) 0.53 
- Summer (June–August) 13 (21) 30 (20) 9 (43) 22 (14) 0.4 (0.1–1.2) 0.08 
- Autumn (September–November) 17 (27) 37 (24) 4 (19) 17 (11) 1.6 (0.4–7.3) 0.57 
- Winter (December–February) 
 
 
22 (35) 64 (42) 3 (14) 74 (47) 3.2 (0.8–18.7) 0.10 
Day-care or pre-/school attendance, n (%) 
 
 





Immunizations1, n (%) 
 
 





Underlying disease, n (%) 
 
10 (16) 32 (21) 12 (57) 137 (88) 0.1 (0.0–0.5) <0.01 
- ENT, n 0 4 12 1372   
- Asthma or history of 
 wheezing, n 
2 8 0 0   
- Cardiovascular, n 0 2 0 0   
- Gastrointestinal, n 2 2 0 0   
- Neurological, n 2 5 0 0   
- Other, n 
 
 
4 11 0 0   
 490	
Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; ENT, ear, nose, and throat; HC, healthy control; IQR, interquartile range; NA, 491	
not available; OR, odds ratio. 492	
 493	
Differences between included CAP and included HC children (in bold) were determined by the Mann-Whitney U test (medians) and Fisher’s exact test 494	
(proportions). P values <0.05 are indicated in bold. 495	
 496	
1
 “Immunizations” refers to being immunized per the national immunization schedule in Switzerland. 497	
2
 Children with elective surgery at the division of otolaryngology (n=137): hyperplasia of adenoids (n=62); eustachian catarrh (n=26); cysts, fistulae, and 498	
sinuses (n=10); protruding ears (n=8); and others (n=31). 499	
 500	
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(n=156)   
Mp-specific DNA 
 
44 (29) 12 (8) 
6/137 (4) elective surgery 
6/19 (32) siblings 
 
4.9 (2.4–10.6) <0.01 
Mp-specific antibodies     
IgM + 39/97* (40) 15/139* (11) 5.5 (2.7–11.7) <0.01 
IgG + 39/97 (40) 16/139 (12) 5.1 (2.6–10.7) <0.01 
IgA + 
 
24/97 (25) 0/139 (0) NA <0.01 
IgM + IgG + 37/97 (38) 7/139 (5) 11.5 (4.7–32.3) <0.01 
IgM + IgA + 24/97 (25) 0/139 (0) NA <0.01 
IgG + IgA + 23/97 (24) 0/139 (0) NA <0.01 
IgM + IgG + IgA + 
 
 






(n=21)   
Mp-specific DNA 
 
32 (51) 10 (48) 
4/12 (33) elective surgery 
6/9 (66) siblings 
 
1.1 (0.4–3.6) 1.00 
Mp-specific antibodies     
IgM + 32 (51) 6 (29) 2.6 (0.8–9.1) 0.08 
IgG + 27 (43) 5 (24) 2.4 (0.7–9.4) 0.19 
IgA + 
 
13 (21) 0 (0) NA 0.03 
IgM + IgG + 26 (41) 5 (24) 2.2 (0.7–8.8) 0.20 
IgM + IgA + 13 (21) 0 (0) NA 0.03 
IgG + IgA + 11 (17) 0 (0) NA 0.06 
IgM + IgG + IgA + 
 
11 (17) 0 (0) NA 0.06 
Seroconversion:     
- IgM 0/38** (0) 0/11** (0) – 1.00 
- IgG 5/38 (13) 1/11 (9) 1.5 (0.1–78.7) 1.00 
- IgA 
 
5/38 (13) 0/11 (0) NA 0.57 
Class switch from IgM to IgG 
 
7/38 (18) 1/11 (9) 2.2 (0.2–111.7) 0.66 
Titer increase:     
- IgM ≥2-fold [3] 3/38 (8) 0/11 (0) NA 1.00 
- IgG ≥4-fold [2] 
 
10/38 (26) 1/11 (9) 3.5 (0.4–170.1) 0.41 
Mp-specific ASC     
IgM ASC + 29 (46) 0 (0) NA <0.01 
IgG ASC + 27 (43) 0 (0) NA <0.01 
IgA ASC + 
 
27 (43) 0 (0) NA <0.01 
IgM ASC + IgG ASC + 27 (43) 0 (0) NA <0.01 
IgM ASC + IgA ASC + 27 (43) 0 (0) NA <0.01 
IgG ASC + IgA ASC + 26 (41) 0 (0) NA <0.01 
IgM ASC + IgG ASC + IgA ASC + 
 
 
26 (41) 0 (0) NA <0.01 
 502	
Abbreviations: ASC, antibody-secreting cell; CAP, community-acquired pneumonia; CI, confidence interval; ELISpot, enzyme-linked immunospot; HC, 503	
healthy control; Ig, immunoglobulin; NA, not available; OR, odds ratio. 504	
 505	
Data are presented as no. (%). Differences between groups are indicated by the Fisher's exact test. P values <0.05 are indicated in bold. *Sera were available in 506	
97 (64%) CAP patients and 139 (89%) controls. **Paired sera were available in 38 (60%) CAP patients and 11 (52%) controls. 507	
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Figures 508	
Figure 1. Study profile. Recruitment and flow of (A) CAP patients and (B) healthy controls 509	
(HC). Abbreviations: CAP, community-acquired pneumonia; HC, healthy control; PBMC, 510	






137 (88%) elective surgery
19 (12%) siblings
450 Children screened
298 (66%) not eligible
196 (66%) <3 years of age
102 (34%) no informed
consent
 
63 (41%) Children included 21 (13%) Children included
12 (57%) elective surgery
9 (43%) siblings
89 (59%) incomplete 
specimens
55 (62%) no blood samples
34 (38%) no fresh PBMCs
(isolated ≤4 h)
135 (87%) incomplete 
specimens
17 (13%) no blood samples
118 (87%) no fresh PBMCs
(isolated ≤4 h)
 
152 (34%) Children enrolled 156 (100%)  Children enrolled
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Figure 2. Kinetics of pharyngeal Mp DNA levels, Mp antibodies, and Mp ASCs in Mp IgM 514	
ASC-positive CAP patients. (A) Mp DNA levels in pharyngeal swab samples as genomic 515	
copy number per ml. (B–D) Mp antibodies and Mp ASCs of the isotype IgM (B), IgG (C), and 516	
IgA (D). Smooth curves fitted by loess (with a span of 0.67) and original data as dots are 517	
shown. The dashed horizontal lines represent the cut-off for the ELISA, lower limits of 518	
quantification for IgM, IgG, and IgA are 5, 3, and 2 U/ml. Abbreviations: ASC, antibody-519	
secreting cell; Ig, immunoglobulin; Mp, M. pneumoniae; PBMC, peripheral blood 520	
mononuclear cell; PCR, polymerase chain reaction. 521	
 522	
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Figure 3. Enzyme-linked immunospot (ELISpot) assay for ASCs in a patient who developed 524	
Mp CAP. Representative patterns of ELISpot assay wells 3 days prior to the onset of 525	
symptoms (A) and on day 6 (B) and day 81 (C) after symptom onset (100,000 PBMCs per 526	
well). Abbreviations: Ig, immunoglobulin; Mp, M. pneumoniae; PBS, phosphate-buffered 527	
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Figure 4. Kinetics of pharyngeal Mp DNA levels, Mp antibodies, and Mp ASCs in Mp PCR-531	
positive controls. (A) Mp DNA levels in pharyngeal swab samples as genomic copy number 532	
per ml. (B–D) Mp antibodies and Mp ASCs of the isotype IgM (B), IgG (C), and IgA (D). 533	
Smooth curves fitted by loess (with a span of 0.67) and original data as dots are shown. The 534	
dashed horizontal lines represent the cut-off for the ELISA, lower limits of quantification for 535	
IgM, IgG, and IgA are 5, 3, and 2 U/ml. Abbreviations: ASC, antibody-secreting cell; Ig, 536	
immunoglobulin; Mp, M. pneumoniae; PBMC, peripheral blood mononuclear cell; PCR, 537	
polymerase chain reaction. 538	
 539	
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Figure 5. Kinetics of pharyngeal Mp DNA levels, Mp-specific antibodies, and ASCs in Mp 542	
IgM ASC-positive CAP patients according to different treatment management. (A) β-lactam 543	
antibiotics (n=7) or no treatment (n=2). (B) Macrolides (Clarithromycin) (n=10). (C) 544	
Doxycycline (n=10). Smooth curves fitted by loess (with a span of 0.67) and original data as 545	
dots are shown. The dashed horizontal lines represent the cut-off for the ELISA (lower limits 546	
of quantification: 5 U/ml). Abbreviations: ASC, antibody-secreting cell; Ig, immunoglobulin; 547	
Mp, M. pneumoniae; PBMC, peripheral blood mononuclear cell; PCR, polymerase chain 548	
reaction. 549	
 550	
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